This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


Psychopharmacology of ADHD: Children and Adolescents

Robert L. Findling, M.D.; and Judith W. Dogin, M.D.

Published: June 1, 1998

Article Abstract

Medications can provide significant salutary effects for children and adolescents with attentiondeficit/hyperactivity disorder (ADHD). Due to their well-established safety and efficacy, psychostimulantsare generally considered first-line pharmacotherapy for most young patients with ADHD.Since psychostimulant treatment often requires frequent dosing and may be associated with unacceptableside effects and risks, other classes of medication have been studied as possible treatment alternatives.The most extensively researched nonstimulant medications are the tricyclic antidepressants. Inaddition, α2 agonists have also been shown to reduce symptoms of ADHD. However, concerns regardingpotential cardiotoxicity have tempered the enthusiasm for both of these classes of medication.Newer antidepressants such as bupropion and venlafaxine may hold promise as treatments for ADHD.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 59

Quick Links: